Navigation Links
Breakthrough in RSV research to help infected children
Date:5/23/2014

Researchers at Le Bonheur Children's Hospital and the University of Tennessee Health Science Center announced results today from a clinical trial of a drug shown to safely reduce the viral load and clinical illness of healthy adult volunteers intranasally infected with respiratory syncytial virus (RSV).

Detailed results of this study were presented by lead researcher Infectious Disease Specialist John DeVincenzo, MD, this week during a poster discussion session at the American Thoracic Society 2014 International Conference in San Diego. He serves as medical director of the Molecular and Viral Diagnostics Laboratories at Le Bonheur Children's Hospital and also serves as a professor of Pediatrics and professor of Microbiology, Immunology, and Biochemistry at the University of Tennessee College of Medicine.

RSV is the most common cause of lower respiratory tract infections in young children in the United States and worldwide. It hospitalizes 125,000 children in the United States each year, and was the cause for 1.5 million outpatient visits, according to the Centers for Disease Control and Prevention (CDC). DeVincenzo and his fellow researchers have been part of virtually every experimental therapeautic advancement, developmental pathway and antiviral therapy created to tackle the virus in the past 15 years. Learn more about his research at lebonheur.org/promise.

The Phase 2a challenge study of Gilead Sciences Inc.'s GS-5806, an investigational oral RSV fusion inhibitor, achieved primary and secondary endpoints of lower viral load, improvements in total mucus weight and symptom diary score compared to placebo. Volunteers in the study were given the oral drug after being infected with RSV using the experimental challenge model based on a clinical isolate from an infant hospitalized with RSV bronchiolitis which can be safely used to infect adults, and that was developed by DeVincenzo in 2007 to test proof-of-concept antivirals.

"No effective antiviral treatments currently exist for RSV, which is the leading cause of severe childhood respiratory infections, and is increasingly recognized as a major cause of serious adult respiratory infections," said DeVincenzo. "Based on the reductions in viral load, reduced clinical symptoms, as well as the safety profile observed in this adult challenge study, clinical trials in naturally infected patients should now be explored."


'/>"/>

Contact: Sara Burnett
Sara.Burnett@lebonheur.org
901-487-0739
Le Bonheur Children's Hospital
Source:Eurekalert

Related medicine news :

1. Breakthrough: Nasal spray may soon replace the pill
2. Breakthrough Research Provides Valuable Insight On Cause Of Alzheimer’s
3. Diverticulitis Breakthrough Review Indicates If This Book Is Reliable – HealthReviewCenter
4. MD Anderson researcher Jim Allison wins Breakthrough Prize for his innovative cancer immunology rese
5. Breakthrough in treating leukemia, lymphoma with umbilical cord blood stem cells
6. Pacific Northwest Dry Eye Sufferers Gain Access to Breakthrough Treatment at Specialty Eyecare Group
7. Noted Experts to Lead Breakthrough Conversation at Center for Hispanic Leadership, December 2nd Hispanics in Healthcare Forum
8. Study reveals potential breakthrough in hearing technology
9. Children’s Cancer & Blood Foundation Breakthrough Ball Gala Honored Margo & John Catsimatidis, Amar’e Stoudemire and Dr. Patricia J. Giardina
10. Effective and Safe Cancer Vaccine? Breakthrough Alternative Cancer Treatment Available Through Special Research Program
11. Voices Against Brain Cancer Comments On Breakthrough Brain Surgery Technique
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... ... May 23, 2017 , ... PM360, the premier information ... announced the winners of its 3rd Annual ELITE Awards. The ELITE (Exceptional • ... the healthcare industry today. , Out of more than 500 submissions, 100 winners ...
(Date:5/23/2017)... ... May 23, 2017 , ... London, May 23, 2017: Walter Schindler, ... this month as a Guest Speaker and Contributor to a weeklong series of classes, ... Purpose. , Walter Schindler and SAIL Capital have received ...
(Date:5/23/2017)... ... May 23, 2017 , ... ... chat as a standard feature on its secure clinical communication platform. The platform ... to video depending on the type and urgency of a situation. , ...
(Date:5/23/2017)... ... May 23, 2017 , ... Therachat , a smart guided journaling ... infographic on the current state of anxiety in support of National Mental Health Awareness ... in April 2017 and benchmarked general anxiety levels as well as identified the top ...
(Date:5/22/2017)... ... May 22, 2017 , ... Today, Our Urgent Care ... with a public ribbon cutting ceremony. Since opening over a month ago, ... to the emergency room. The new Our Urgent Care walk-in clinic is located ...
Breaking Medicine News(10 mins):
(Date:5/9/2017)... WASHINGTON , May 9, 2017  Demonstrating ... the board of directors for the Pharmaceutical Research ... criteria for membership. Biopharmaceutical companies will now have ... in order to be eligible to join PhRMA. ... criteria, the board is sending a clear message ...
(Date:5/9/2017)... Ore. , May 9, 2017  Semler ... that provides technology solutions to improve the clinical ... financial results for the first quarter ended March ... our products enable our customers to identify when ... to intervene before events like heart attacks or ...
(Date:5/8/2017)... FLINT, Mich. , May 8, 2017  Diplomat ... WRB Communications, Inc. ("WRB"), a health care ... . WRB specializes in relationship management ... organizations. WRB will ... of Diplomat,s commercialization support services for manufacturers, biotech firms, ...
Breaking Medicine Technology: